

AMENDMENTS TO THE CLAIMS

This listing of the claims will replace all prior versions, and listings, of claims in the application:

1-16 (Cancelled)

17. (Currently Amended) A method for treating Alzheimer's disease in a patient diagnosed with the Alzheimer's disease, comprising:

withdrawing blood containing blood cells from the patient;

separating the blood cells from the blood to yield a naturally occurring plasma from the patient;

exposing the naturally occurring plasma from the patient to a lipid removing agent to derive a partially delipidated plasma having a lower content of at least one of triglycerides or cholesterol than the naturally occurring plasma; and,

administering to the patient an amount of a composition comprising ~~[[a]] the partially delipidated plasma having a lower content of at least one of triglycerides or cholesterol than a naturally occurring plasma,~~ wherein the amount is effective to treat the Alzheimer's disease in the patient.

18. (Previously Presented) The method of Claim 17, wherein the partially delipidated plasma has a lower content of triglycerides and cholesterol than the naturally occurring plasma.

19. (Previously Presented) The method of Claim 17, wherein the partially delipidated plasma comprises a partially delipidated high density lipoprotein having a lower level of cholesterol than a high density lipoprotein in the naturally occurring plasma and a partially delipidated low density lipoprotein having a lower level of cholesterol than a low density lipoprotein in the naturally occurring plasma.

20. (Cancelled).

21. (Currently Amended) The method of Claim ~~[[20]]~~ 17, wherein the lipid removing agent comprises an ether.
22. (Currently Amended) The method of Claim ~~[[20]]~~ 17, wherein the lipid removing agent comprises a combination of an alcohol and an ether.
23. (Cancelled).
24. (Currently Amended) The method of Claim ~~[[23]]~~ 17, further comprising, a step of separating the partially delipidated plasma from the lipid removing agent before administering the partially delipidated plasma to the patient.
25. (Previously Presented). The method of Claim 17, wherein the method reduces amyloid plaque, decreases neurofibrillary tangles, reduces levels of A β , alters a ratio of A β 40 to A β 42, affects enzymatic processing of APP, or reduces levels of phosphorylated tau protein, or a combination thereof, in the patient.
26. (Previously Presented) The method of Claim 17, wherein the patient has increased blood cholesterol levels.
27. (Previously Presented) The method of Claim 17, wherein the method reduces dementia in the patient.
- 28-39. (Cancelled)